Industry Research Reports

Home > Reports > Medical Care > Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Industry: Medical Care

Published Date: 2026-02-14

Pages: 108 Pages

Report ld: 5555455

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Peptide Therapeutics Market Size(US$)

CAGR 2026-2032

9.0%

Market Size,2032

USD 80,340

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 47,910 million

Market Forecast in 2032(Value)

US$ 80,340 million

CAGR

9.0%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Peptide Therapeutics market size was US$ 44320 million in 2025 and is forecast to reach a readjusted size of US$ 80340 million by 2032 with a CAGR of 9.0% during the forecast period 2026-2032.

Peptide therapeutics are a class of pharmaceutical drugs composed of short chains of amino acids, typically ranging from 2 to 50 residues, that mimic natural peptides in the body. These drugs are designed to interact with specific cellular targets, such as receptors, enzymes, or ion channels, to regulate physiological functions. Due to their high specificity, low toxicity, and favorable safety profiles, peptide drugs are widely used in the treatment of various diseases, including cancer, diabetes, cardiovascular diseases, and infectious conditions. With advances in peptide engineering, formulation, and delivery technologies, peptide therapeutics have become a growing segment of the biopharmaceutical industry.The average gross profit margin of this product is 70%.

The Peptide Therapeutics market is driven by the increasing demand for highly specific and efficient treatments for a wide range of diseases, including cancer, diabetes, cardiovascular conditions, and rare genetic disorders. Peptides, due to their high selectivity, low immunogenicity, and close resemblance to natural biological molecules, are well-suited for targeted therapy with fewer side effects. Technological advancements in peptide synthesis, modification, and drug delivery systems have enhanced their stability and extended their half-life, making them more viable for clinical use. Additionally, the growing investment in biopharmaceutical research and development, along with a favorable regulatory environment for innovative therapies, is accelerating the development and approval of peptide-based drugs.

Despite these advantages, the Peptide Therapeutics market faces several challenges, particularly related to drug delivery and manufacturing. Peptides are generally unstable in the gastrointestinal tract and are rapidly degraded by enzymes, limiting their oral bioavailability and often requiring parenteral administration. This can affect patient compliance and limit market penetration. Moreover, the complex and costly manufacturing processes for peptide drugs, including synthesis, purification, and formulation, pose economic and technical barriers, especially for smaller biotech firms. Overcoming these limitations through innovative formulation strategies and cost-efficient production methods is critical for ensuring broader clinical adoption and long-term market growth.

The global Peptide Therapeutics market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.

MARKET SEGMENTATION

By Company

Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
J & J
Aurinia Pharmaceuticals
BioMarin Pharmaceutical
Apellis Pharmaceuticals
Lantheus
CSL Vifor Group

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Injection
Oral
Other

Segment by Application

Cancer
Metabolic Disorders
Central Nervous System
Other

Segment by Category

Agonist/Analog
Antagonist
Enzyme Inhibitor
Ion Channel

Segment by Division

Retail
Hospital
Other

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Peptide Therapeutics value chain, addressing:

- Market entry risks/opportunities by region

- Product mix optimization based on local practices

- Competitor tactics in fragmented vs. consolidated markets

biaoTi QYRESEARCH'S STRENGTHS

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market by Type

1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032

1.2.2 Injection

1.2.3 Oral

1.2.4 Other

1.3 Market by Application

1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032

1.3.2 Cancer

1.3.3 Metabolic Disorders

1.3.4 Central Nervous System

1.3.5 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Peptide Therapeutics Market Perspective (2021-2032)

2.2 Global Market Size by Region: 2021 vs 2025 vs 2032

2.3 Global Peptide Therapeutics Market Share by Revenue, by Region (2021-2026)

2.4 Global Peptide Therapeutics Revenue Forecast by Region (2027-2032)

2.5 Major Regions and Emerging Markets Analysis

2.5.1 North America Peptide Therapeutics Market Size and Prospective (2021-2032)

2.5.2 Europe Peptide Therapeutics Market Size and Prospective (2021-2032)

2.5.3 China Peptide Therapeutics Market Size and Prospective (2021-2032)

2.5.4 Japan Peptide Therapeutics Market Size and Prospective (2021-2032)

2.5.5 India Peptide Therapeutics Market Size and Prospective (2021-2032)

2.5.6 South America Peptide Therapeutics Market Size and Prospective (2021-2032)

3 Breakdown Data by Type

3.1 Global Peptide Therapeutics Historical Market Size by Type (2021-2026)

3.2 Global Peptide Therapeutics Forecasted Market Size by Type (2027-2032)

3.3 Representative Players for Different Types of Peptide Therapeutics

4 Breakdown Data by Application

4.1 Global Peptide Therapeutics Historical Market Size by Application (2021-2026)

4.2 Global Peptide Therapeutics Forecasted Market Size by Application (2027-2032)

4.3 New Sources of Growth in Peptide Therapeutics Applications

5 Competitive Landscape by Players

5.1 Global Top Players by Revenue

5.1.1 Global Top Peptide Therapeutics Players by Revenue (2021-2026)

5.1.2 Global Peptide Therapeutics Market Share by Revenue, by Players (2021-2026)

5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

5.3 Players Covered: Ranking by Peptide Therapeutics Revenue

5.4 Global Peptide Therapeutics Market Concentration Analysis

5.4.1 Global Peptide Therapeutics Market Concentration Ratio (CR5 and HHI)

5.4.2 Global Top 10 and Top 5 Companies by Peptide Therapeutics Revenue in 2025

5.5 Global Key Players of Peptide Therapeutics Head Offices and Areas Served

5.6 Global Key Players of Peptide Therapeutics, Product and Application

5.7 Global Key Players of Peptide Therapeutics, Date of Entry into This Industry

5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments, Downstream and Major Customers

6.1.1 North America Peptide Therapeutics Revenue by Company (2021-2026)

6.1.2 North America Market Size by Type

6.1.2.1 North America Peptide Therapeutics Market Size by Type (2021-2026)

6.1.2.2 North America Peptide Therapeutics Market Share by Type (2021-2026)

6.1.3 North America Market Size by Application

6.1.3.1 North America Peptide Therapeutics Market Size by Application (2021-2026)

6.1.3.2 North America Peptide Therapeutics Market Share by Application (2021-2026)

6.1.4 North America Peptide Therapeutics Major Customers

6.1.5 North America Market Trends and Opportunities

6.2 Europe Market: Players, Segments, Downstream and Major Customers

6.2.1 Europe Peptide Therapeutics Revenue by Company (2021-2026)

6.2.2 Europe Market Size by Type

6.2.2.1 Europe Peptide Therapeutics Market Size by Type (2021-2026)

6.2.2.2 Europe Peptide Therapeutics Market Share by Type (2021-2026)

6.2.3 Europe Market Size by Application

6.2.3.1 Europe Peptide Therapeutics Market Size by Application (2021-2026)

6.2.3.2 Europe Peptide Therapeutics Market Share by Application (2021-2026)

6.2.4 Europe Peptide Therapeutics Major Customers

6.2.5 Europe Market Trends and Opportunities

6.3 China Market: Players, Segments, Downstream and Major Customers

6.3.1 China Peptide Therapeutics Revenue by Company (2021-2026)

6.3.2 China Market Size by Type

6.3.2.1 China Peptide Therapeutics Market Size by Type (2021-2026)

6.3.2.2 China Peptide Therapeutics Market Share by Type (2021-2026)

6.3.3 China Market Size by Application

6.3.3.1 China Peptide Therapeutics Market Size by Application (2021-2026)

6.3.3.2 China Peptide Therapeutics Market Share by Application (2021-2026)

6.3.4 China Peptide Therapeutics Major Customers

6.3.5 China Market Trends and Opportunities

6.4 Japan Market: Players, Segments, Downstream and Major Customers

6.4.1 Japan Peptide Therapeutics Revenue by Company (2021-2026)

6.4.2 Japan Market Size by Type

6.4.2.1 Japan Peptide Therapeutics Market Size by Type (2021-2026)

6.4.2.2 Japan Peptide Therapeutics Market Share by Type (2021-2026)

6.4.3 Japan Market Size by Application

6.4.3.1 Japan Peptide Therapeutics Market Size by Application (2021-2026)

6.4.3.2 Japan Peptide Therapeutics Market Share by Application (2021-2026)

6.4.4 Japan Peptide Therapeutics Major Customers

6.4.5 Japan Market Trends and Opportunities

6.5 India Market: Players, Segments, Downstream and Major Customers

6.5.1 India Peptide Therapeutics Revenue by Company (2021-2026)

6.5.2 India Market Size by Type

6.5.2.1 India Peptide Therapeutics Market Size by Type (2021-2026)

6.5.2.2 India Peptide Therapeutics Market Share by Type (2021-2026)

6.5.3 India Market Size by Application

6.5.3.1 India Peptide Therapeutics Market Size by Application (2021-2026)

6.5.3.2 India Peptide Therapeutics Market Share by Application (2021-2026)

6.5.4 India Peptide Therapeutics Major Customers

6.5.5 India Market Trends and Opportunities

6.6 South America Market: Players, Segments, Downstream and Major Customers

6.6.1 South America Peptide Therapeutics Revenue by Company (2021-2026)

6.6.2 South America Market Size by Type

6.6.2.1 South America Peptide Therapeutics Market Size by Type (2021-2026)

6.6.2.2 South America Peptide Therapeutics Market Share by Type (2021-2026)

6.6.3 South America Market Size by Application

6.6.3.1 South America Peptide Therapeutics Market Size by Application (2021-2026)

6.6.3.2 South America Peptide Therapeutics Market Share by Application (2021-2026)

6.6.4 South America Peptide Therapeutics Major Customers

6.6.5 South America Market Trends and Opportunities

7 Key Player Profiles

7.1 Sanofi

7.1.1 Sanofi Company Details

7.1.2 Sanofi Business Overview

7.1.3 Sanofi Peptide Therapeutics Introduction

7.1.4 Sanofi Revenue in Peptide Therapeutics Business (2021-2026)

7.1.5 Sanofi Recent Development

7.2 Teva

7.2.1 Teva Company Details

7.2.2 Teva Business Overview

7.2.3 Teva Peptide Therapeutics Introduction

7.2.4 Teva Revenue in Peptide Therapeutics Business (2021-2026)

7.2.5 Teva Recent Development

7.3 Novo Nordisk

7.3.1 Novo Nordisk Company Details

7.3.2 Novo Nordisk Business Overview

7.3.3 Novo Nordisk Peptide Therapeutics Introduction

7.3.4 Novo Nordisk Revenue in Peptide Therapeutics Business (2021-2026)

7.3.5 Novo Nordisk Recent Development

7.4 Takeda

7.4.1 Takeda Company Details

7.4.2 Takeda Business Overview

7.4.3 Takeda Peptide Therapeutics Introduction

7.4.4 Takeda Revenue in Peptide Therapeutics Business (2021-2026)

7.4.5 Takeda Recent Development

7.5 Eli Lilly

7.5.1 Eli Lilly Company Details

7.5.2 Eli Lilly Business Overview

7.5.3 Eli Lilly Peptide Therapeutics Introduction

7.5.4 Eli Lilly Revenue in Peptide Therapeutics Business (2021-2026)

7.5.5 Eli Lilly Recent Development

7.6 AstraZeneca

7.6.1 AstraZeneca Company Details

7.6.2 AstraZeneca Business Overview

7.6.3 AstraZeneca Peptide Therapeutics Introduction

7.6.4 AstraZeneca Revenue in Peptide Therapeutics Business (2021-2026)

7.6.5 AstraZeneca Recent Development

7.7 Novartis

7.7.1 Novartis Company Details

7.7.2 Novartis Business Overview

7.7.3 Novartis Peptide Therapeutics Introduction

7.7.4 Novartis Revenue in Peptide Therapeutics Business (2021-2026)

7.7.5 Novartis Recent Development

7.8 AbbVie

7.8.1 AbbVie Company Details

7.8.2 AbbVie Business Overview

7.8.3 AbbVie Peptide Therapeutics Introduction

7.8.4 AbbVie Revenue in Peptide Therapeutics Business (2021-2026)

7.8.5 AbbVie Recent Development

7.9 Ipsen

7.9.1 Ipsen Company Details

7.9.2 Ipsen Business Overview

7.9.3 Ipsen Peptide Therapeutics Introduction

7.9.4 Ipsen Revenue in Peptide Therapeutics Business (2021-2026)

7.9.5 Ipsen Recent Development

7.10 Ferring

7.10.1 Ferring Company Details

7.10.2 Ferring Business Overview

7.10.3 Ferring Peptide Therapeutics Introduction

7.10.4 Ferring Revenue in Peptide Therapeutics Business (2021-2026)

7.10.5 Ferring Recent Development

7.11 Merck

7.11.1 Merck Company Details

7.11.2 Merck Business Overview

7.11.3 Merck Peptide Therapeutics Introduction

7.11.4 Merck Revenue in Peptide Therapeutics Business (2021-2026)

7.11.5 Merck Recent Development

7.12 The Medicines

7.12.1 The Medicines Company Details

7.12.2 The Medicines Business Overview

7.12.3 The Medicines Peptide Therapeutics Introduction

7.12.4 The Medicines Revenue in Peptide Therapeutics Business (2021-2026)

7.12.5 The Medicines Recent Development

7.13 J & J

7.13.1 J & J Company Details

7.13.2 J & J Business Overview

7.13.3 J & J Peptide Therapeutics Introduction

7.13.4 J & J Revenue in Peptide Therapeutics Business (2021-2026)

7.13.5 J & J Recent Development

7.14 Aurinia Pharmaceuticals

7.14.1 Aurinia Pharmaceuticals Company Details

7.14.2 Aurinia Pharmaceuticals Business Overview

7.14.3 Aurinia Pharmaceuticals Peptide Therapeutics Introduction

7.14.4 Aurinia Pharmaceuticals Revenue in Peptide Therapeutics Business (2021-2026)

7.14.5 Aurinia Pharmaceuticals Recent Development

7.15 BioMarin Pharmaceutical

7.15.1 BioMarin Pharmaceutical Company Details

7.15.2 BioMarin Pharmaceutical Business Overview

7.15.3 BioMarin Pharmaceutical Peptide Therapeutics Introduction

7.15.4 BioMarin Pharmaceutical Revenue in Peptide Therapeutics Business (2021-2026)

7.15.5 BioMarin Pharmaceutical Recent Development

7.16 Apellis Pharmaceuticals

7.16.1 Apellis Pharmaceuticals Company Details

7.16.2 Apellis Pharmaceuticals Business Overview

7.16.3 Apellis Pharmaceuticals Peptide Therapeutics Introduction

7.16.4 Apellis Pharmaceuticals Revenue in Peptide Therapeutics Business (2021-2026)

7.16.5 Apellis Pharmaceuticals Recent Development

7.17 Lantheus

7.17.1 Lantheus Company Details

7.17.2 Lantheus Business Overview

7.17.3 Lantheus Peptide Therapeutics Introduction

7.17.4 Lantheus Revenue in Peptide Therapeutics Business (2021-2026)

7.17.5 Lantheus Recent Development

7.18 CSL Vifor Group

7.18.1 CSL Vifor Group Company Details

7.18.2 CSL Vifor Group Business Overview

7.18.3 CSL Vifor Group Peptide Therapeutics Introduction

7.18.4 CSL Vifor Group Revenue in Peptide Therapeutics Business (2021-2026)

7.18.5 CSL Vifor Group Recent Development

8 Peptide Therapeutics Market Dynamics

8.1 Peptide Therapeutics Industry Trends

8.2 Peptide Therapeutics Market Drivers

8.3 Peptide Therapeutics Market Challenges

8.4 Peptide Therapeutics Market Restraints

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Peptide Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Global Peptide Therapeutics Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 3. Global Market Peptide Therapeutics Market Size (US$ Million) by Region:2021 vs 2025 vs 2032

Table 4. Global Peptide Therapeutics Revenue (US$ Million) Market Share by Region (2021-2026)

Table 5. Global Peptide Therapeutics Revenue Share by Region (2021-2026)

Table 6. Global Peptide Therapeutics Revenue (US$ Million) Forecast by Region (2027-2032)

Table 7. Global Peptide Therapeutics Revenue Share Forecast by Region (2027-2032)

Table 8. Global Peptide Therapeutics Market Size by Type (2021-2026) & (US$ Million)

Table 9. Global Peptide Therapeutics Market Share by Revenue, by Type (2021-2026)

Table 10. Global Peptide Therapeutics Forecasted Market Size by Type (2027-2032) & (US$ Million)

Table 11. Global Peptide Therapeutics Market Share by Revenue, by Type (2027-2032)

Table 12. Representative Players of Each Type

Table 13. Global Peptide Therapeutics Market Size by Application (2021-2026) & (US$ Million)

Table 14. Global Peptide Therapeutics Market Share by Revenue, by Application (2021-2026)

Table 15. Global Peptide Therapeutics Forecasted Market Size by Application (2027-2032) & (US$ Million)

Table 16. Global Peptide Therapeutics Market Share by Revenue, by Application (2027-2032)

Table 17. New Sources of Growth in Peptide Therapeutics Applications

Table 18. Global Peptide Therapeutics Revenue by Players (2021-2026) & (US$ Million)

Table 19. Global Peptide Therapeutics Market Share by Players (2021-2026)

Table 20. Global Top Peptide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Therapeutics as of 2025)

Table 21. Ranking of Global Top Peptide Therapeutics Companies by Revenue (US$ Million) in 2025

Table 22. Global 5 Largest Players Market Share by Peptide Therapeutics Revenue (CR5 and HHI) & (2021-2026)

Table 23. Global Key Players of Peptide Therapeutics, Headquarters and Area Served

Table 24. Global Key Players of Peptide Therapeutics, Product and Application

Table 25. Global Key Players of Peptide Therapeutics, Date of Entry into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. North America Peptide Therapeutics Revenue by Company (2021-2026) & (US$ Million)

Table 28. North America Peptide Therapeutics Market Share by Revenue, by Company (2021-2026)

Table 29. North America Peptide Therapeutics Market Size by Type (2021-2026) & (US$ Million)

Table 30. North America Peptide Therapeutics Market Size by Application (2021-2026) & (US$ Million)

Table 31. Europe Peptide Therapeutics Revenue by Company (2021-2026) & (US$ Million)

Table 32. Europe Peptide Therapeutics Market Share by Revenue, by Company (2021-2026)

Table 33. Europe Peptide Therapeutics Market Size by Type (2021-2026) & (US$ Million)

Table 34. Europe Peptide Therapeutics Market Size by Application (2021-2026) & (US$ Million)

Table 35. China Peptide Therapeutics Revenue by Company (2021-2026) & (US$ Million)

Table 36. China Peptide Therapeutics Market Share by Revenue, by Company (2021-2026)

Table 37. China Peptide Therapeutics Market Size by Type (2021-2026) & (US$ Million)

Table 38. China Peptide Therapeutics Market Size by Application (2021-2026) & (US$ Million)

Table 39. Japan Peptide Therapeutics Revenue by Company (2021-2026) & (US$ Million)

Table 40. Japan Peptide Therapeutics Market Share by Revenue, by Company (2021-2026)

Table 41. Japan Peptide Therapeutics Market Size by Type (2021-2026) & (US$ Million)

Table 42. Japan Peptide Therapeutics Market Size by Application (2021-2026) & (US$ Million)

Table 43. India Peptide Therapeutics Revenue by Company (2021-2026) & (US$ Million)

Table 44. India Peptide Therapeutics Market Share by Revenue, by Company (2021-2026)

Table 45. India Peptide Therapeutics Market Size by Type (2021-2026) & (US$ Million)

Table 46. India Peptide Therapeutics Market Size by Application (2021-2026) & (US$ Million)

Table 47. South America Peptide Therapeutics Revenue by Company (2021-2026) & (US$ Million)

Table 48. South America Peptide Therapeutics Market Share by Revenue, by Company (2021-2026)

Table 49. South America Peptide Therapeutics Market Size by Type (2021-2026) & (US$ Million)

Table 50. South America Peptide Therapeutics Market Size by Application (2021-2026) & (US$ Million)

Table 51. Sanofi Company Details

Table 52. Sanofi Business Overview

Table 53. Sanofi Peptide Therapeutics Product

Table 54. Sanofi Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 55. Sanofi Recent Development

Table 56. Teva Company Details

Table 57. Teva Business Overview

Table 58. Teva Peptide Therapeutics Product

Table 59. Teva Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 60. Teva Recent Development

Table 61. Novo Nordisk Company Details

Table 62. Novo Nordisk Business Overview

Table 63. Novo Nordisk Peptide Therapeutics Product

Table 64. Novo Nordisk Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 65. Novo Nordisk Recent Development

Table 66. Takeda Company Details

Table 67. Takeda Business Overview

Table 68. Takeda Peptide Therapeutics Product

Table 69. Takeda Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 70. Takeda Recent Development

Table 71. Eli Lilly Company Details

Table 72. Eli Lilly Business Overview

Table 73. Eli Lilly Peptide Therapeutics Product

Table 74. Eli Lilly Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 75. Eli Lilly Recent Development

Table 76. AstraZeneca Company Details

Table 77. AstraZeneca Business Overview

Table 78. AstraZeneca Peptide Therapeutics Product

Table 79. AstraZeneca Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 80. AstraZeneca Recent Development

Table 81. Novartis Company Details

Table 82. Novartis Business Overview

Table 83. Novartis Peptide Therapeutics Product

Table 84. Novartis Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 85. Novartis Recent Development

Table 86. AbbVie Company Details

Table 87. AbbVie Business Overview

Table 88. AbbVie Peptide Therapeutics Product

Table 89. AbbVie Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 90. AbbVie Recent Development

Table 91. Ipsen Company Details

Table 92. Ipsen Business Overview

Table 93. Ipsen Peptide Therapeutics Product

Table 94. Ipsen Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 95. Ipsen Recent Development

Table 96. Ferring Company Details

Table 97. Ferring Business Overview

Table 98. Ferring Peptide Therapeutics Product

Table 99. Ferring Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 100. Ferring Recent Development

Table 101. Merck Company Details

Table 102. Merck Business Overview

Table 103. Merck Peptide Therapeutics Product

Table 104. Merck Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 105. Merck Recent Development

Table 106. The Medicines Company Details

Table 107. The Medicines Business Overview

Table 108. The Medicines Peptide Therapeutics Product

Table 109. The Medicines Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 110. The Medicines Recent Development

Table 111. J & J Company Details

Table 112. J & J Business Overview

Table 113. J & J Peptide Therapeutics Product

Table 114. J & J Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 115. J & J Recent Development

Table 116. Aurinia Pharmaceuticals Company Details

Table 117. Aurinia Pharmaceuticals Business Overview

Table 118. Aurinia Pharmaceuticals Peptide Therapeutics Product

Table 119. Aurinia Pharmaceuticals Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 120. Aurinia Pharmaceuticals Recent Development

Table 121. BioMarin Pharmaceutical Company Details

Table 122. BioMarin Pharmaceutical Business Overview

Table 123. BioMarin Pharmaceutical Peptide Therapeutics Product

Table 124. BioMarin Pharmaceutical Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 125. BioMarin Pharmaceutical Recent Development

Table 126. Apellis Pharmaceuticals Company Details

Table 127. Apellis Pharmaceuticals Business Overview

Table 128. Apellis Pharmaceuticals Peptide Therapeutics Product

Table 129. Apellis Pharmaceuticals Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 130. Apellis Pharmaceuticals Recent Development

Table 131. Lantheus Company Details

Table 132. Lantheus Business Overview

Table 133. Lantheus Peptide Therapeutics Product

Table 134. Lantheus Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 135. Lantheus Recent Development

Table 136. CSL Vifor Group Company Details

Table 137. CSL Vifor Group Business Overview

Table 138. CSL Vifor Group Peptide Therapeutics Product

Table 139. CSL Vifor Group Revenue in Peptide Therapeutics Business (2021-2026) & (US$ Million)

Table 140. CSL Vifor Group Recent Development

Table 141. Peptide Therapeutics Market Trends

Table 142. Peptide Therapeutics Market Drivers

Table 143. Peptide Therapeutics Market Challenges

Table 144. Peptide Therapeutics Market Restraints

Table 145. Research Programs/Design for This Report

Table 146. Key Data Information from Secondary Sources

Table 147. Key Data Information from Primary Sources

List of Figures

Figure 1. Peptide Therapeutics Product Picture

Figure 2. Global Peptide Therapeutics Market Share by Type: 2025 vs 2032

Figure 3. Injection Features

Figure 4. Oral Features

Figure 5. Other Features

Figure 6. Global Peptide Therapeutics Market Share by Application: 2025 vs 2032

Figure 7. Cancer

Figure 8. Metabolic Disorders

Figure 9. Central Nervous System

Figure 10. Other

Figure 11. Peptide Therapeutics Report Years Considered

Figure 12. Global Peptide Therapeutics Market Size (US$ Million), Year-over-Year: 2021-2032

Figure 13. Global Peptide Therapeutics Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global Peptide Therapeutics Market Share by Revenue, by Region: 2021 vs 2025

Figure 15. North America Peptide Therapeutics Revenue (US$ Million) Growth Rate (2021-2032)

Figure 16. Europe Peptide Therapeutics Revenue (US$ Million) Growth Rate (2021-2032)

Figure 17. China Peptide Therapeutics Revenue (US$ Million) Growth Rate (2021-2032)

Figure 18. Japan Peptide Therapeutics Revenue (US$ Million) Growth Rate (2021-2032)

Figure 19. India Peptide Therapeutics Revenue (US$ Million) Growth Rate (2021-2032)

Figure 20. South America Peptide Therapeutics Revenue (US$ Million) Growth Rate (2021-2032)

Figure 21. Global Peptide Therapeutics Market Share by Players in 2025

Figure 22. Global Top Peptide Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Therapeutics as of 2025)

Figure 23. The Top 10 and 5 Players Market Share by Peptide Therapeutics Revenue in 2025

Figure 24. North America Peptide Therapeutics Market Share by Type (2021-2026)

Figure 25. North America Peptide Therapeutics Market Share by Application (2021-2026)

Figure 26. Europe Peptide Therapeutics Market Share by Type (2021-2026)

Figure 27. Europe Peptide Therapeutics Market Share by Application (2021-2026)

Figure 28. China Peptide Therapeutics Market Share by Type (2021-2026)

Figure 29. China Peptide Therapeutics Market Share by Application (2021-2026)

Figure 30. Japan Peptide Therapeutics Market Share by Type (2021-2026)

Figure 31. Japan Peptide Therapeutics Market Share by Application (2021-2026)

Figure 32. India Peptide Therapeutics Market Share by Type (2021-2026)

Figure 33. India Peptide Therapeutics Market Share by Application (2021-2026)

Figure 34. South America Peptide Therapeutics Market Share by Type (2021-2026)

Figure 35. South America Peptide Therapeutics Market Share by Application (2021-2026)

Figure 36. Sanofi Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 37. Teva Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 38. Novo Nordisk Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 39. Takeda Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 40. Eli Lilly Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 41. AstraZeneca Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 42. Novartis Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 43. AbbVie Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 44. Ipsen Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 45. Ferring Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 46. Merck Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 47. The Medicines Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 48. J & J Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 49. Aurinia Pharmaceuticals Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 50. BioMarin Pharmaceutical Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 51. Apellis Pharmaceuticals Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 52. Lantheus Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 53. CSL Vifor Group Revenue Growth Rate in Peptide Therapeutics Business (2021-2026)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

Figure 56. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Peptide Therapeutics market? zhanKai

The top companies in the global Peptide Therapeutics market are Sanofi、Teva、Novo Nordisk.

What was the global market size of Peptide Therapeutics in 2032? shouQi

What was the global market size of Peptide Therapeutics in 2026? shouQi

Which region is expected to have the highest market share? shouQi

What is the annual compound growth rate of the global Peptide Therapeutics market size from 2026 to 2032? shouQi

Related Reports

Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 80340 million by 2032, at a CAGR of 9.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-02-14
Pages: 152
USD 4900.00
(Single User License)
Global Peptide Therapeutics Market Research Report 2026
The global Peptide Therapeutics market was valued at US$ 44320 million in 2025 and is anticipated to reach US$ 80340 million by 2032, at a CAGR of 9.0% from 2026 to 2032.
Published Date: 2026-02-14
Pages: 131
USD 2900.00
(Single User License)
Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Peptide Therapeutics was estimated to be worth US$ 44320 million in 2025 and is projected to reach US$ 80340 million, growing at a CAGR of 9.0% from 2026 to 2032.
Published Date: 2026-02-14
Pages: 122
USD 3950.00
(Single User License)
Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 41000 million in 2024 to US$ 74320 million by 2031, at a CAGR of 9.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-09-11
Pages: 151
USD 4900.00
(Single User License)
Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-05-24
Pages: 139
USD 3950.00
(Single User License)
Global Peptide Therapeutics Market Insights, Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 74320 million by 2031, at a Compound Annual Growth Rate (CAGR) of 9.0% during the forecast period.
Published Date: 2025-05-24
Pages: 158
USD 4900.00
(Single User License)
Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Peptide Therapeutics market size was US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-05-24
Pages: 110
USD 4250.00
(Single User License)
Global Peptide Therapeutics Market Research Report 2025
The global market for Peptide Therapeutics was valued at US$ 41000 million in the year 2024 and is projected to reach a revised size of US$ 74320 million by 2031, growing at a CAGR of 9.0% during the forecast period.
Published Date: 2025-05-24
Pages: 94
USD 2900.00
(Single User License)
Global Peptide Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Peptide Therapeutics was estimated to be worth US$ 41000 million and is forecast to reach approximately US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 143
USD 5900.00
(Single User License)
Peptide Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 120
USD 3950.00
(Single User License)

Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 80340 million by 2032, at a CAGR of 9.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-02-14
Pages: 152
USD 4900.00 (Single User License)
Global Peptide Therapeutics Market Research Report 2026
The global Peptide Therapeutics market was valued at US$ 44320 million in 2025 and is anticipated to reach US$ 80340 million by 2032, at a CAGR of 9.0% from 2026 to 2032.
Published: 2026-02-14
Pages: 131
USD 2900.00 (Single User License)
Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Peptide Therapeutics was estimated to be worth US$ 44320 million in 2025 and is projected to reach US$ 80340 million, growing at a CAGR of 9.0% from 2026 to 2032.
Published: 2026-02-14
Pages: 122
USD 3950.00 (Single User License)
Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 41000 million in 2024 to US$ 74320 million by 2031, at a CAGR of 9.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-09-11
Pages: 151
USD 4900.00 (Single User License)
Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-05-24
Pages: 139
USD 3950.00 (Single User License)
Global Peptide Therapeutics Market Insights, Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 74320 million by 2031, at a Compound Annual Growth Rate (CAGR) of 9.0% during the forecast period.
Published: 2025-05-24
Pages: 158
USD 4900.00 (Single User License)
Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Peptide Therapeutics market size was US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-05-24
Pages: 110
USD 4250.00 (Single User License)
Global Peptide Therapeutics Market Research Report 2025
The global market for Peptide Therapeutics was valued at US$ 41000 million in the year 2024 and is projected to reach a revised size of US$ 74320 million by 2031, growing at a CAGR of 9.0% during the forecast period.
Published: 2025-05-24
Pages: 94
USD 2900.00 (Single User License)
Global Peptide Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Peptide Therapeutics was estimated to be worth US$ 41000 million and is forecast to reach approximately US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 143
USD 5900.00 (Single User License)
Peptide Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 120
USD 3950.00 (Single User License)